|
Volumn 3, Issue 16, 2011, Pages 1799-1803
|
Understanding and mitigating impact of immunogenicity on pharmacokinetic assays
a
BIOGEN
(United States)
b
MS RD DMPK/rADME
*
(Germany)
|
Author keywords
anti drug antibodies; immunogenicity; interference; pharmacodynamics; pharmacokinetic
|
Indexed keywords
DRUG;
DRUG ANTIBODY;
MONOCLONAL ANTIBODY;
ANTIBODY AFFINITY;
ANTIBODY SPECIFICITY;
ANTIGEN ANTIBODY COMPLEX;
BINDING ASSAY;
BINDING SITE;
DRUG DETERMINATION;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG HALF LIFE;
DRUG INDUSTRY;
DRUG SAFETY;
IMMUNE RESPONSE;
IMMUNOGENICITY;
LIGAND BINDING;
LIQUID CHROMATOGRAPHY;
MASS SPECTROMETRY;
NONHUMAN;
PHARMACODYNAMICS;
PHARMACOKINETICS;
REVIEW;
WESTERN BLOTTING;
BIOTECHNOLOGY;
DRUG DESIGN;
FEMALE;
HUMANS;
IMMUNOGENETIC PROCESSES;
MALE;
PHARMACOKINETICS;
|
EID: 80052500100
PISSN: 17576180
EISSN: 17576199
Source Type: Journal
DOI: 10.4155/bio.11.162 Document Type: Review |
Times cited : (16)
|
References (4)
|